Page last updated: 2024-10-26

etanidazole and Adenocarcinoma, Basal Cell

etanidazole has been researched along with Adenocarcinoma, Basal Cell in 14 studies

Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.

Research Excerpts

ExcerptRelevanceReference
" Changes in tumor hypoxia were assessed by comparing the binding of two hypoxia tracers, pimonidazole and EF5 given before and after Atrasentan administration."7.75Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. ( Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM, 2009)
"RTOG Protocol 90-20 was designed to evaluate the effect of the hypoxic cell sensitizer Etanidazole (SR-2508) on locally advanced adenocarcinoma of the prostate treated with concurrent external beam irradiation."5.08Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). ( Buzydlowski, JW; Coleman, CN; DelRowe, JD; Forman, JD; Lawton, CA; Marcial, VA; Rotman, M, 1996)
"Fifty eight previously untreated patients with locally advanced adenocarcinoma of the prostate were entered on a Phase II trial of etanidazole (ETA) combined with standard external beam radiation therapy."5.07Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer. ( Beard, C; Buswell, L; Coleman, CN; Johnson, D; Noll, L; Rose, MA, 1994)
" Changes in tumor hypoxia were assessed by comparing the binding of two hypoxia tracers, pimonidazole and EF5 given before and after Atrasentan administration."3.75Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. ( Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM, 2009)
" The secondary goal was to prospectively evaluate the utility of pharmacokinetic monitoring and dose-modification of the incidence and severity of the dose-limiting peripheral neurotoxicity."2.67The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer. ( Buswell, L; Coleman, CN; Noll, L; Riese, N; Rose, MA, 1992)
"Pimonidazole was given 1h preheating, EF5 at various times during or after treatment, 1h later the animals were sacrificed."1.35Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry. ( Humm, JL; Li, GC; Li, XF; Ling, CC; Russell, J; Sun, X; Urano, M; Xing, L, 2008)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19902 (14.29)18.7374
1990's9 (64.29)18.2507
2000's2 (14.29)29.6817
2010's1 (7.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ali, R1
Apte, S1
Vilalta, M1
Subbarayan, M1
Miao, Z1
Chin, FT1
Graves, EE1
Sun, X1
Li, XF2
Russell, J2
Xing, L1
Urano, M1
Li, GC1
Humm, JL1
Ling, CC2
Yang, KM1
Lupu, ME1
Cho, H1
Koutcher, JA1
Tamulevicius, P1
Streffer, C1
Blanke, G1
Luscher, G1
Beard, C2
Buswell, L4
Rose, MA2
Noll, L2
Johnson, D1
Coleman, CN4
Watkins-Bruner, D1
Scott, C1
Lawton, C1
DelRowe, J1
Rotman, M2
Cella, D1
Bornstein, BA1
Zouranjian, PS1
Hansen, JL1
Fraser, SM1
Gelwan, LA1
Teicher, BA2
Svensson, GK1
Recht, A1
Clark, J1
Ravikumar, T1
Busse, PM1
O'Dwyer, PJ1
Panting, L1
LaCreta, FP1
Clapper, ML1
Holden, SA1
Goff, DA1
Wright, JE1
Tretyakov, O1
Ayash, LJ1
Lawton, CA1
Buzydlowski, JW1
Forman, JD1
Marcial, VA1
DelRowe, JD1
Riese, N1
Taghian, A1
Lespinasse, F1
Guichard, ME1
Newman, HF1
Bleehen, NM1
Workman, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomized Phase II Trial[NCT02567253]Phase 256 participants (Actual)Interventional2016-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

5 trials available for etanidazole and Adenocarcinoma, Basal Cell

ArticleYear
Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer.
    International journal of radiation oncology, biology, physics, 1994, Jun-15, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Etanidazole; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms

1994
RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer.
    International journal of radiation oncology, biology, physics, 1995, Nov-01, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Aged; Data Collection; Etanidazole; Feasibility Studies; Follow-Up Studies; Humans;

1995
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
    International journal of radiation oncology, biology, physics, 1994, Jun-15, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1994
Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).
    International journal of radiation oncology, biology, physics, 1996, Oct-01, Volume: 36, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Etanidazole; Humans; Male; Middle Aged; Neoplasm Staging; P

1996
The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
    International journal of radiation oncology, biology, physics, 1992, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Male; Nitroimidazol

1992

Other Studies

9 other studies available for etanidazole and Adenocarcinoma, Basal Cell

ArticleYear
18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Adenocarcinoma; Animals; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Dose Fractionation, Radiation; E

2015
Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 88, Issue:2

    Topics: Adenocarcinoma; Analysis of Variance; Animals; Cell Hypoxia; Colorectal Neoplasms; Etanidazole; Fema

2008
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.
    Cancer biology & therapy, 2009, Volume: 8, Issue:20

    Topics: Adenocarcinoma; Animals; Atrasentan; Colonic Neoplasms; Combined Modality Therapy; Etanidazole; Gado

2009
The effects of radiosensitizers on intermediary metabolism in vivo.
    International journal of radiation oncology, biology, physics, 1984, Volume: 10, Issue:8

    Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adenocarcinoma; Animals; Dihydroxyacetone Phosphate; Etanidazo

1984
Local hyperthermia, radiation therapy, and chemotherapy in patients with local-regional recurrence of breast carcinoma.
    International journal of radiation oncology, biology, physics, 1993, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neopl

1993
SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma.
    Biochemical pharmacology, 1993, Oct-05, Volume: 46, Issue:7

    Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Etanidazole; Glutathione; Glutathione Transfe

1993
Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro

1996
Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts.
    International journal of radiation oncology, biology, physics, 1991, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Animals; Cell Survival; Drug Synergism; Etanidazole; Female; Humans; Melanoma; Mice;

1991
A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.
    The British journal of radiology, 1986, Volume: 59, Issue:700

    Topics: Adenocarcinoma; Drug Combinations; Drug Evaluation; Etanidazole; Humans; Melanoma; Nitroimidazoles;

1986
chemdatabank.com